API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. KO /
  3. 170900.KO

Dong-A St (170900 KO) stock market data APIs

₩62100 400(0.6%) as of November 25, 2024
Price chart is built with Anychart

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab. to treat gastritis; Suganon tab./Sugamet XR tab. for type 2 diabetes mellitus; Terizidone tab to treat active pulmonary and extra-pulmonary tuberculosis; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Dong-A St Financial Data Overview

61700
62100
-
64100
61300
55493.0495-88000
555 453 M
8 988 K
675 406 M
-1011.3472
0.0113
0.601
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '170900',
Type: 'Common Stock',
Name: 'Dong-A St',
Exchange: 'KO',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
OpenFigi: NULL,
ISIN: 'KR7170900005',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
}

Dong-A St Fundamental Data is available in our Financial Data APIs

  • Net Revenue 675 406 M
  • EBITDA 9 979 M
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Dong-A St Earnings via APIs

  • Latest Release 2024-11-01
  • EPS/Forecast NaN

Get Dong-A St End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Dong-A St latest news via APIs

NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…

By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT We are initiating coverage of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) with a valuation of $25.00. NeuroBo is a biopharmaceutic...

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

- Following EMA, FDA accepted BLA for DMB-3115 SEOUL, South Korea, January 05, 2024--(BUSINESS WIRE)--Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subs...
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com